Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.

被引：0
|
作者：
Bezares, R.
Stemmelin, G.
Argentieri, D.
Lanari, E.
Guy-Garay, E.
Campestri, R.
Bartomioli, M.
Garcia, J.
Giralt, S.
Milone, G.
机构：
[1] Hosp Gen Agudos, Buenos Aires, DF, Argentina
[2] Hosp Britan, Buenos Aires, DF, Argentina
[3] Sanatorio Mitre, Buenos Aires, DF, Argentina
[4] Ctr Med Corrientes, Buenos Aires, DF, Argentina
[5] CEMIC, Buenos Aires, DF, Argentina
[6] Hosp Pena Bahia Blanca, Buenos Aires, DF, Argentina
[7] Hosp Privado Cordova, Cordova, Argentina
[8] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Fundaleu, Buenos Aires, DF, Argentina
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360S / 360S
页数：1
相关论文
共 50 条
  • [31] Interim report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, H
    Moreton, P
    Richard, JA
    Andy, RC
    Sheila, O
    Paul, E
    Anthony, C
    Claire, D
    Estella, M
    Andrew, PR
    Daniel, KB
    Peter, H
    BLOOD, 2005, 106 (11) : 599A - 600A
  • [32] Hematological recovery after administration of subcutaneous alemtuzumab (MabCampath®) in previously untreated versus refractory B-CLL.
    Lundin, J
    Kimby, E
    Mellstedt, H
    Dyer, MJS
    Hillman, P
    Kennedy, B
    Osterborg, A
    BLOOD, 2002, 100 (11) : 805A - 805A
  • [33] Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)
    Sayala, HA
    Moreton, P
    Jones, RA
    Rawstron, AC
    O'Connor, SJ
    Evans, P
    Carter, A
    Dearden, C
    Matutes, E
    Pettitt, AR
    Kennedy, DB
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 3 - 3
  • [34] Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy C.
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 14A - 15A
  • [35] Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis.
    Rai, KR
    Coutre, S
    Rizzieri, D
    Gribben, JG
    Flinn, I
    Rabinowe, S
    Keating, MJ
    BLOOD, 2001, 98 (11) : 365A - 365A
  • [36] Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia
    Hyunkyung Park
    Jeonghwan Youk
    Inho Kim
    Sung-Soo Yoon
    Seonyang Park
    Jeong-Ok Lee
    Soo-Mee Bang
    Youngil Koh
    Annals of Hematology, 2016, 95 : 1777 - 1786
  • [37] FLUDARABINE IN UNTREATED AND PREVIOUSLY TREATED B-CLL PATIENTS - A REPORT ON EFFICIENCY AND TOXICITY
    SPRIANO, M
    CLAVIO, M
    CARRARA, P
    CANEPA, L
    MIGLINO, M
    PIERRI, I
    CELESTI, L
    ROSSI, E
    VIMERCATI, R
    BRUNI, R
    SANTINI, G
    GATTI, AM
    STURA, P
    GHIO, R
    PATRONE, F
    DAMASIO, E
    GOBBI, M
    HAEMATOLOGICA, 1994, 79 (03) : 218 - 224
  • [38] Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine.
    Keating, MJ
    Byrd, J
    Rai, K
    Flinn, I
    Jain, V
    Binet, JL
    Bolin, R
    Hillmen, P
    Hutchinson, M
    BLOOD, 1999, 94 (10) : 705A - 705A
  • [39] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Ricci, Francesca
    Vismara, Eleonora
    Ciapanna, Denis
    Petrizzi, Valeria Belsito
    Crugnola, Monica
    Spriano, Mauro
    Uziel, Lilj
    De Blasio, Angelo
    Spedini, Pierangelo
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 922A - 922A
  • [40] Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen
    Wang, San-Bin
    Li, Li
    Pan, Xin-Hua
    Hu, Deng-Ming
    Peng, Li-Hui
    Liu, Lin
    Xie, Zheng-Jun
    Yin, Bo
    Sun, Xiao-Juan
    Yu, Jing
    Liang, Yang
    CLINICAL TRANSPLANTATION, 2013, 27 (02) : E109 - E115
12345